Q2 EPS Estimates for Lam Research Boosted by Zacks Research

Lam Research Corporation (NASDAQ:LRCX) – Investment analysts at Zacks Research raised their Q2 2026 earnings per share (EPS) estimates for shares of Lam Research in a research report issued to clients and investors on Wednesday, November 12th. Zacks Research analyst Team now anticipates that the semiconductor company will post earnings per share of $1.13 for the quarter, up from their previous estimate of $0.99. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Lam Research’s current full-year earnings is $3.71 per share. Zacks Research also issued estimates for Lam Research’s Q3 2026 earnings at $1.14 EPS, Q4 2026 earnings at $1.11 EPS, FY2026 earnings at $4.64 EPS, Q1 2027 earnings at $1.19 EPS, Q2 2027 earnings at $1.26 EPS, Q3 2027 earnings at $1.27 EPS, Q4 2027 earnings at $1.24 EPS, Q1 2028 earnings at $1.34 EPS and FY2028 earnings at $5.66 EPS.

LRCX has been the topic of several other reports. HSBC set a $127.00 price objective on Lam Research and gave the stock a “hold” rating in a report on Tuesday, September 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Lam Research in a report on Thursday, October 23rd. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Lam Research from $150.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Evercore ISI boosted their target price on shares of Lam Research from $115.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, October 23rd. Finally, Raymond James Financial increased their price target on shares of Lam Research from $90.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-six have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $149.04.

Lam Research Stock Down 4.3%

Shares of NASDAQ LRCX traded down $6.94 during midday trading on Thursday, reaching $154.48. 3,268,005 shares of the company’s stock were exchanged, compared to its average volume of 11,785,017. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.60 and a current ratio of 2.21. Lam Research has a 52-week low of $56.32 and a 52-week high of $167.15. The business’s fifty day moving average price is $138.78 and its two-hundred day moving average price is $108.56. The stock has a market capitalization of $194.04 billion, a PE ratio of 34.02, a price-to-earnings-growth ratio of 1.68 and a beta of 1.87.

Lam Research (NASDAQ:LRCX) last issued its quarterly earnings data on Wednesday, October 22nd. The semiconductor company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.04. Lam Research had a net margin of 29.66% and a return on equity of 60.60%. The company had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.23 billion. During the same quarter last year, the company earned $0.86 earnings per share. Lam Research’s revenue for the quarter was up 27.7% on a year-over-year basis. Lam Research has set its Q2 2026 guidance at 1.050-1.250 EPS.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. IMG Wealth Management Inc. bought a new stake in shares of Lam Research in the 2nd quarter valued at approximately $26,000. Howard Hughes Medical Institute bought a new position in Lam Research during the second quarter valued at approximately $27,000. Sound Income Strategies LLC acquired a new stake in Lam Research in the third quarter valued at approximately $41,000. Tripletail Wealth Management LLC acquired a new stake in Lam Research in the third quarter valued at approximately $44,000. Finally, Strategic Wealth Investment Group LLC bought a new stake in Lam Research in the second quarter worth approximately $29,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

Insider Buying and Selling at Lam Research

In other Lam Research news, Director Bethany Mayer sold 1,298 shares of Lam Research stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $159.99, for a total transaction of $207,667.02. Following the sale, the director owned 1,652 shares of the company’s stock, valued at $264,303.48. The trade was a 44.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Vahid Vahedi sold 52,190 shares of the business’s stock in a transaction on Monday, October 13th. The stock was sold at an average price of $138.90, for a total value of $7,249,191.00. Following the transaction, the senior vice president owned 251,047 shares of the company’s stock, valued at $34,870,428.30. This trade represents a 17.21% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 62,528 shares of company stock worth $8,880,448. 0.31% of the stock is owned by company insiders.

Lam Research Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 7th. Shareholders of record on Wednesday, December 3rd will be given a $0.26 dividend. The ex-dividend date is Wednesday, December 3rd. This represents a $1.04 annualized dividend and a yield of 0.7%. Lam Research’s dividend payout ratio is 22.91%.

About Lam Research

Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.